Radiomedix Receives Btd for Alphamedix

RadioMedix, Orano Med receive US FDA breakthrough therapy designation for AlphaMedix in gastroenteropancreatic neuroendocrine tumours

RadioMedix, Inc, a clinical-stage biotechnology company and sponsor of the AlphaMedix clinical trials, based in Houston, and Orano Med, a clinical-stage biotechnology company develops a new generation of targeted therapies against cancer, both clinical stage radiopharmaceutical companies, jointly announced that the FDA has granted breakthrough therapy designation (BTD) to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). 

AlphaMedix

AlphaMedix is a Targeted Alpha Therapy currently in phase 2 clinical development, which consists of an SSTR-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. Due to their high energy and short path length, alpha emitters enable specific targeting and killing of individual cancer cells, while minimizing toxicity to surrounding healthy tissue. AlphaMedix is the first Targeted Alpha Therapy to receive Breakthrough Therapy Designation.

Words from the Sponsor

The US FDA's breakthrough therapy designation underscores AlphaMedix potential as an innovative treatment that could redefine how patients with neurendocrine tumours are treated. We believe that AlphaMedix has potential to demonstrate substantial benefit over currently FDA approved PRRT with beta-particle emitters for patients with metastatic or inoperable SSTR-expressing GEP-NETs. The FDA's decision is a great news for patients suffering from this illness, and an important milestone to expedite the development of this new therapy,” said Ebrahim Delpassand, MD, chairman and chief executive officer of RadioMedix.

Responses from Phase I & II

• The breakthrough therapy designation is based on the results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedix. 
• In the phase 1 study, treatment was well-tolerated, with a response rate (ORR according to RECIST 1.1) of 62.5% for the GEP-NET patients who had never received PRRT with Lutathera, which is based on the beta-particle emitter Lutetium-177. 
• In the phase 2 trial, the target response rate has already been achieved ahead of top-line data, expected in mid-2024.

Message Form Therapy Developers

Receiving the US FDA breakthrough therapy designation for AlphaMedix is a great achievement for everyone involved and confirms the strong interest of the medical community for Targeted Alpha Therapies with lead-212. Based on positive results from our clinical studies to date, we are convinced that Targeted Alpha Therapies, such as AlphaMedix, will lead the next generation of radioligand therapies, providing increased cytotoxicity against cancer cells but limited toxicity to adjacent healthy cells. This recognition from the FDA reinforces Orano Med’s commitment to make innovative lead-212-based therapies available to the medical community and patients worldwide,” said Julien Dodet, president and chief executive officer of Orano Med.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!